Lucid Diligence Brief: General Proximity and Daiichi Sankyo multi-target induced-proximity oncology deal
Lucid Diligence Brief: General Proximity and Daiichi Sankyo multi-target…
Lucid Diligence Brief: Galecto acquires Damora Therapeutics
Lucid Diligence Brief: Galecto acquires Damora Therapeutics Professional…
Lucid Diligence Brief: Iambic raises $100M+ for AI drug discovery
Lucid Diligence Brief: Iambic raises $100M+ for AI drug discovery Professional…
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding
Lucid Diligence Brief: Accipiter Bio $12.7M Seed Funding Professional audiences…
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing
Lucid Diligence Brief: Azalea Therapeutics launches with $82M financing…
Lucid Diligence Brief: NEOK Bio $75M Series A
Lucid Diligence Brief: NEOK Bio $75M Series A Professional audiences only. Not…
Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027
Lucid Diligence Brief: Evaxion $7.2m runway extension to H2 2027 Professional…
Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC
Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC Professional…
Lucid Diligence Brief: Takeda and Innovent global oncology partnership
Lucid Diligence Brief: Takeda and Innovent global oncology partnership…
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics Professional…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…
Oncology Today: ADCs, PD-L1 & FDA Wins (Oct 6–13, 2025)
This week’s oncology highlights include breakthrough therapies such as ADCs…